Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 4—April 2004
Research

Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs

Emily L.C. Tan*, Eng Eong Ooi†, Chin-Yo Lin*, Hwee Cheng Tan†, Ai Ee Ling‡, Bing Lim*, and Lawrence W. Stanton*Comments to Author 
Author affiliations: *Genome Institute of Singapore, Singapore; †National Environmental Agency, Singapore; ‡Singapore General Hospital, Singapore

Main Article

Figure 2

Dose-response curves for Alferon (a), Betaferon (b), and Multiferon (c) as determined by plaque reduction assays. IC50 (50% inhibitory concentration) and IC95 (95% inhibitory concentration) values were calculated by using the fitted functions describing the curves.

Figure 2. Dose-response curves for Alferon (a), Betaferon (b), and Multiferon (c) as determined by plaque reduction assays. IC50 (50% inhibitory concentration) and IC95 (95% inhibitory concentration) values were calculated by using the fitted functions describing the curves.

Main Article

Page created: February 09, 2011
Page updated: February 09, 2011
Page reviewed: February 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external